Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2025, Xeris Biopharma (XERS) reported revenue of $74.38 million, up 37.1% over the same period last year. EPS came in at $0, compared to -$0.06 in the year-ago quarter.The reported revenue represents a surprise of +0.04% over the Zacks Consensus Estimate of $74.35 million. With the consensus EPS estimate being $0.01, the EPS surprise was -100%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Product Revenue- Gvoke: $25.15 million versus the three-analyst average estimate of $26.22 million.Product Revenue- Keveyis: $11.94 million compared to the $36.23 million average estimate based on three analysts.Revenue- Royalty, contract and other: $0.32 million versus $1.58 million estimated by three analysts on average.Revenue- Product revenue, net: $74.06 million versus $73.01 million estimated by three analysts on average.Product Revenue- Recorlev: $36.98 million versus the three-analyst average estimate of $10.55 million.View all Key Company Metrics for Xeris Biopharma here>>>Shares of Xeris Biopharma have returned +20.4% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks